IDH1 and central nervous system cancer: IDH-O gliomas have overall slightly better prognosis than IDH-A [21], despite their elevated cell cycle activity, possibly because of its composite character in bulk transcriptomics originating from different cell types and also other factors such as tumor microenvironment, eventually affecting prognosis.